Nanobead-based interventions for the treatment and prevention of tuberculosis

被引:126
作者
Griffiths, Gareth [1 ]
Nystroem, Bo [2 ]
Sable, Suraj B. [3 ]
Khuller, Gopal K. [4 ]
机构
[1] Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway
[2] Univ Oslo, Dept Chem, N-0315 Oslo, Norway
[3] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA
[4] Postgrad Inst Med Educ & Res, Dept Biochem, Chandigarh 160012, India
关键词
DRUG-DELIVERY-SYSTEM; MYCOBACTERIUM-TUBERCULOSIS; PROTECTIVE EFFICACY; IMMUNE-RESPONSE; DENDRITIC CELLS; DNA VACCINE; NANOPARTICLES; RESISTANT; MICROPARTICLES; IMMUNOGENICITY;
D O I
10.1038/nrmicro2437
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is one of the most devastating bacterial diseases to affect humans. M. tuberculosis is a robust pathogen that has evolved the capacity to survive and grow inside macrophage phagosomes. A cocktail of antibiotics has long been successfully used against M. tuberculosis but is becoming less effective owing to the emergence of multidrug resistance. The only available preventive vaccine, using Mycobacterium bovis bacille Calmette-Guerin, is considered to be ineffective against adult pulmonary TB, the most prevalent form of the disease. Here, we review the potential use of biodegradable nanoparticle-based anti-TB drug delivery systems that have been shown to be more effective against M. tuberculosis in animal models than conventional antibiotic treatment regimens. This technology also has substantial potential for vaccination and other therapeutic strategies against TB and other infectious diseases.
引用
收藏
页码:827 / 834
页数:8
相关论文
共 70 条
[1]
The potential of azole antifungals against latent/persistent tuberculosis [J].
Ahmad, Z ;
Sharma, S ;
Khuller, GK .
FEMS MICROBIOLOGY LETTERS, 2006, 258 (02) :200-203
[2]
Ahmad Z, 2008, EXPERT OPIN DRUG DEL, V5, P1323, DOI [10.1517/17425240802600662, 10.1517/17425240802600662 ]
[3]
Ajdary S, 2007, VACCINE, V25, P4595, DOI 10.1016/j.vaccine.2007.03.039
[4]
Bacteria-mediated delivery of nanoparticles and cargo into cells [J].
Akin, Demir ;
Sturgis, Jennifer ;
Ragheb, Kathy ;
Sherman, Debby ;
Burkholder, Kristin ;
Robinson, J. Paul ;
Bhunia, Arun K. ;
Mohammed, Sulma ;
Bashir, Rashid .
NATURE NANOTECHNOLOGY, 2007, 2 (07) :441-449
[5]
Amaral L., 2007, Infectious Disorders - Drug Targets, V7, P257, DOI 10.2174/187152607782110022
[6]
Vaccine strategies against latent tuberculosis infection [J].
Andersen, Peter .
TRENDS IN MICROBIOLOGY, 2007, 15 (01) :7-13
[7]
Biodegradation and biocompatibility of PLA and PLGA microspheres [J].
Anderson, JM ;
Shive, MS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24
[8]
Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages [J].
Anisimova, Y. V. ;
Gelperina, S. I. ;
Peloquin, C. A. ;
Heifets, L. B. .
JOURNAL OF NANOPARTICLE RESEARCH, 2000, 2 (02) :165-171
[9]
Scavenger receptors: role in innate immunity and microbial pathogenesis [J].
Areschoug, Thomas ;
Gordon, Siamon .
CELLULAR MICROBIOLOGY, 2009, 11 (08) :1160-1169
[10]
Host innate immune response to Mycobacterium tuberculosis [J].
Bhatt, Kamlesh ;
Salgame, Padmini .
JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (04) :347-362